Status:
COMPLETED
Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis
Lead Sponsor:
Retina Institute of Hawaii
Conditions:
Wet AMD
Eligibility:
All Genders
Brief Summary
The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.
Detailed Description
To determine mean change in visual acuity at 6 and 12 months
Eligibility Criteria
Inclusion
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Age greater then and equal 50 years
- Patients with active neovascular AMD
- Received at least 3 treatments with anti-VEGF therapy (bevacizumab or pegaptanib or ranibizumab) in the last 24 months
- If the patient has bilateral disease and qualifies for the study, both eyes may be included
Exclusion
- Subjects who meet any of the following criteria will be excluded from this study:
- Pregnancy or lactation
- Premenopausal women not using adequate contraception.
- Participation in another simultaneous medical investigation
Key Trial Info
Start Date :
February 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00804934
Start Date
February 1 2008
End Date
January 1 2009
Last Update
May 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina Institute of Hawaii
Honolulu, Hawaii, United States, 96815